Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Susanne Mayer-Wagner has a total of 192 co-authors. Here are the top co-authors by number of shared publications:

  • Volkmar Jansson

    Department of Orthopaedic Surgery, Physical Medicine and Rehabilitation, Ludwig-Maximilians-University, Munich, Germany

    9 shared publications
  • Peter E. Müller

    Department of Orthopaedic Surgery, Physical Medicine and Rehabilitation, Ludwig-Maximilians-University, Munich, Germany

    8 shared publications
  • Boris Michael Holzapfel

    Department of Orthopaedics and Trauma Surgery, Musculoskeletal University Center Munich (MUM), University Hospital, LMU Munich, Munich, Germany

    6 shared publications
  • Bärbel Schmitt

    Department of Orthopaedics, Physical Medicine and Rehabilitation, University Hospital, LMU Munich, Marchioninistraße 15, 81377 Munich, Germany

    5 shared publications
  • Julia I. Redeker

    Department of Orthopaedics and Trauma Surgery, Musculoskeletal University Center Munich (MUM), University Hospital, Ludwig Maximilian University (LMU) Munich, Munich, Germany

    5 shared publications
  • Manuel Weißenberger

    Department of Orthopaedic Surgery, Koenig-Ludwig-Haus, University of Wuerzburg, 97074 Wuerzburg, Germany

    4 shared publications

Latest Publications

  • Open Access

    Diverging trends in primary and revision arthroplasty in Germany: projections and implications for healthcare delivery for the next ten years

    by Dirk Linke, Gautier Beckers, Bernd Kladny, Susanne Mayer-Wagner, Maximilian Rudert, Boris Michael Holzapfel, Ioannis Stratos

    Summary: Purpose: To analyze nationwide trends, demographic changes, and future projections of primary and revision hip and knee arthroplasty in Germany. Methods: Nationwide data from the German Federal Statistical Office and hospital quality reports (2015–2024) were analyzed regarding procedure volumes, age distribution, hospital stay, and structural care changes. Future case numbers until 2035 were projected using age-specific incidence rates and population forecasts. Results: Primary hip and knee arthroplasty volumes increased significantly, with annual growth rates of + 4,986 cases for hip (p = 0.005) and + 5,727 cases for knee arthroplasty (p = 0.028), whereas revision procedures remained stable (hip: p = 0.065; knee: p = 0.947). Age-stratified analyses demonstrated a shift toward older patients, with increasing proportions in age groups ≥ 60 years and declining shares among patients ≤ 50 years. Projections to 2035 indicate stable overall primary procedure numbers (+ 637 cases), with an increase in hip arthroplasty (+ 11,202 cases) and a decrease in knee arthroplasty (− 10,565 cases), while revision procedures are expected to rise by + 3,158 cases, particularly in patients > 75 years. Length of hospital stay decreased significantly across all procedures (− 0.38 to − 0.46 days per year; p < 0.001), and the number of hospitals declined markedly between 2019 and 2024 (− 19.2 to − 25.6 hospitals per year), reflecting increasing centralization of primary care, whereas revision procedures remained widely distributed, also across low-volume centers. Conclusion: These findings reveal a growing mismatch between increasing demand, demographic changes, and current care structures, underscoring the need for targeted adaptations in arthroplasty care delivery.

  • Pertrochantäre Frakturen

    by Carl Neuerburg, Susanne Mayer-Wagner, Cornelia Lützner, Yunjie Zhang, Stefanie Deckert, Anna Fuhrmann


  • Open Access

    Clinical translation of 3D-printed patient-specific bone implants: a consensus statement

    by Markus MD Laubach, Giles Michael Beng (Hons) Cheers, Tina Msc Frankenbach-Désor, Lucas Philipp Md Weimer, Heiko Baumgartner, Wolfgang Böcker, Rainer Burgkart, Gianluca Cidonio, Matteo D’ESte, Ulrich Dirnagl, et al.

    Background: Extensive defects in long bones, resulting from trauma, disease, or other etiologies, impose significant morbidity on patients and may necessitate amputation, long-term disability, or premature mortality. While three-dimensional (3D)-printed, patient-specific implants offer promising regenerative solutions, their clinical implementation remains hindered by regulatory challenges, lack of standardized guidelines, and gaps in translational research. Addressing these barriers is critical to improving patient outcomes and optimizing healthcare resource utilization. Materials and methods: A multidisciplinary group of 29 experts – including clinicians (surgeons, anesthesiologists), biomaterial scientists, biomedical engineers, legal/regulatory professionals, health economists, meta-researchers, artificial intelligence experts, trialists, and biomaterial industry representatives – convened for the Consensus Meeting on 3D-printed patient-specific Bone Implants (CoMBI). Preceding the meeting, key questions were discussed in individual interviews and categorized into fundamental research, preclinical studies, and clinical trials and implementation (CoMBI themes). Experts presented on each theme, followed by structured discussions. Statements were synthesized, iteratively refined, and validated through open review. Results: The consensus meeting resulted in 20 key statements addressing the CoMBI themes, outlining a framework to advance regulatory compliance and facilitate the clinical adoption of 3D-printed implants. Key statements include the need for harmonized regulatory pathways, clear guidelines on preclinical validation, and innovative trial designs tailored to complex, patient-specific implants. Strengthening collaboration among policymakers, regulatory agencies, and clinicians is crucial to overcoming current implementation barriers and ensuring equitable patient access to these advanced technologies. Conclusion: This Consensus Statement presents 20 key statements across fundamental research, preclinical studies, and clinical trials and implementation, offering a roadmap for accelerating the regulatory and clinical translation of 3D-printed patient-specific bone implants. The findings emphasize the critical role of interdisciplinary collaboration in overcoming challenges, such as standardizing implant development and navigating complex regulatory landscapes. By addressing these barriers and outlining practical strategies, the consensus highlights actionable steps to bridge the gap between innovation and clinical application.


  • Open Access

    MRI as a viable alternative to CT for 3D surgical planning of cavitary bone tumors

    by Yooseok Chae, Giles Michael Cheers, MinJoo Kim, Paul Reidler, Alexander Klein, Thomas Fevens, Boris Michael Holzapfel, Susanne Mayer-Wagner


  • Open Access

    Tissue-engineered patient-derived osteosarcoma models dissecting tumour-bone interactions

    by Tina Frankenbach-Désor, Isabella Niesner, Parveen Ahmed, Hans Roland Dürr, Alexander Klein, Thomas Knösel, Jonathan Gospos, Jacqui A. McGovern, Dietmar W. Hutmacher, Boris M. Holzapfel, et al.

    Osteosarcoma is the most common malignant bone tumor, primarily affecting children and young adults. For these young patients, the current treatment options for osteosarcoma impose considerable constraints on daily life with significant morbidity and a low survival rate. Despite ongoing research efforts, the 5-year survival rate of first-diagnosed patients without metastases has not changed in the past four decades. The demand for novel treatments is currently still unmet, in particular for effective second-line therapy. Therefore, there is an urgent need for advanced preclinical models and drug-testing platforms that take into account the complex disease characteristics, the high heterogeneity of the tumour and the interactions with the bone microenvironment. In this review, we provide a comprehensive overview about state-of-the-art tissue-engineered and patient-specific models for osteosarcoma. These sophisticated platforms for advanced therapy trials aim to improve treatment outcomes for future patients by modelling the patient’s disease state in a more accurate and complex way, thus improving the quality of preclinical research studies. Graphical Abstract


  • Open Access

    Does Combined Treatment with Tranexamic Acid and Vancomycin Affect Human Chondrocytes In Vitro?

    by Mike Wagenbrenner, Tizian Heinz, Philip M. Anderson, Ioannis Stratos, Joerg Arnholdt, Susanne Mayer-Wagner, Konstantin Horas, Denitsa Docheva, Boris M. Holzapfel, Maximilian Rudert, et al.

    Background: The aim of our study was to examine the combined effects of tranexamic acid (TXA) and vancomycin powder (VP) on chondrocytes in vitro. Despite the use of TXA and VP being linked to a reduced risk of extensive postoperative blood loss and periprosthetic joint infections (PJIs) in TKA, the possible cytotoxic side effects on periarticular cell types remain unclear. Methods: Human chondrocytes were harvested from hyaline cartilage and expanded in monolayer culture before being simultaneously exposed to different concentrations of TXA and VP for varying exposure times. Cell viability and proliferation were assessed using an ATP assay and an Annexin 5 assay, respectively, while changes in the relative expression of chondrogenic marker genes were examined using semiquantitative RT-PCR. Results: The simultaneous exposure of chondrocytes to TXA and VP for more than 48 h led to a reduction in both cell viability and proliferation rates. When exposing chondrocytes to the lowest examined concentrations of both TXA (10 mg/mL) and VP (3 mg/mL), the observed effects were delayed until 96 h. However, our study found no dependencies of the observed effects on the concentrations tested. Further, we found no effects on the expression of chondrogenic marker genes. Conclusions: Consequently, limiting the exposure time of chondrocytes to TXA and VP in an in vitro setting to 24 h may be considered safe and could help to further improve the understanding of the safe use of substances in vivo. However, further in vitro research is required to develop a comprehensive understanding of the effects of both VP and TXA on important periarticular cell types in TKA, including chondrocytes, osteocytes, and tenocytes.


  • Open Access

    Clinical challenges in prostate cancer management: Metastatic bone-tropism and the role of circulating tumor cells

    by Gayathri K. Guruvayurappan, Tina Frankenbach-Désor, Markus Laubach, Alexander Klein, Michael von Bergwelt-Baildon, Monica Cusan, Attila Aszodi, Boris M. Holzapfel, Wolfgang Böcker, Susanne Mayer-Wagner


  • Open Access

    Zinc-Doped Bioactive Glass/Polycaprolactone Hybrid Scaffolds Manufactured by Direct and Indirect 3D Printing Methods for Bone Regeneration

    by Nafise Elahpour, Isabella Niesner, Cédric Bossard, Nora Abdellaoui, Valérie Montouillout, Franck Fayon, Christine Taviot-Guého, Tina Frankenbach, Alexander Crispin, Pardis Khosravani, et al.

    A novel organic–inorganic hybrid, based on SiO2-CaO-ZnO bioactive glass (BG) and polycaprolactone (PCL), associating the highly bioactive and versatile bioactive glass with clinically established PCL was examined. The BG–PCL hybrid is obtained by acid-catalyzed silica sol–gel process inside PCL solution either by direct or indirect printing. Apatite-formation tests in simulated body fluid (SBF) confirm the ion release along with the hybrid’s bone-like apatite forming. Kinetics differ significantly between directly and indirectly printed scaffolds, the former requiring longer periods to degrade, while the latter demonstrates faster calcium phosphate (CaP) formation. Remarkably, Zn diffusion and accumulation are observed at the surface within the newly formed active CaP layer. Zn release is found to be dependent on printing method and immersion medium. Investigation of BG at the atomic scale reveals the ambivalent role of Zn, capable of acting both as a network modifier and as a network former linking the BG silicate network. In addition, hMSCs viability assay proves no cytotoxicity of the Zn hybrid. LIVE/DEAD staining demonstrated excellent cell viability and proliferation for over seven weeks. Overall, this hybrid material either non-doped or doped with a metal trace element is a promising candidate to be translated to clinical applications for bone regeneration.


  • Open Access

    Mesenchymal Stromal Cells (MSCs) Isolated from Various Tissues of the Human Arthritic Knee Joint Possess Similar Multipotent Differentiation Potential

    by Mike Wagenbrenner, Konrad Poker, Tizian Heinz, Marietta Herrmann, Konstantin Horas, Regina Ebert, Susanne Mayer-Wagner, Boris M. Holzapfel, Maximilian Rudert, Andre F. Steinert, et al.

    (1) Background: The mesenchymal stromal cells (MSCs) of different tissue origins are applied in cell-based chondrogenic regeneration. However, there is a lack of comparability determining the most suitable cell source for the tissue engineering (TE) of cartilage. The purpose of this study was to compare the in vitro chondrogenic potential of MSC-like cells from different tissue sources (bone marrow, meniscus, anterior cruciate ligament, synovial membrane, and the infrapatellar fat pad removed during total knee arthroplasty (TKA)) and define which cell source is best suited for cartilage regeneration. (2) Methods: MSC-like cells were isolated from five donors and expanded using adherent monolayer cultures. Differentiation was induced by culture media containing specific growth factors. Transforming growth factor (TGF)-ß1 was used as the growth factor for chondrogenic differentiation. Osteogenesis and adipogenesis were induced in monolayer cultures for 27 days, while pellet cell cultures were used for chondrogenesis for 21 days. Control cultures were maintained under the same conditions. After, the differentiation period samples were analyzed, using histological and immunohistochemical staining, as well as molecularbiological analysis by RT-PCR, to assess the expression of specific marker genes. (3) Results: Plastic-adherent growth and in vitro trilineage differentiation capacity of all isolated cells were proven. Flow cytometry revealed the clear co-expression of surface markers CD44, CD73, CD90, and CD105 on all isolated cells. Adipogenesis was validated through the formation of lipid droplets, while osteogenesis was proven by the formation of calcium deposits within differentiated cell cultures. The formation of proteoglycans was observed during chondrogenesis in pellet cultures, with immunohistochemical staining revealing an increased relative gene expression of collagen type II. RT-PCR proved an elevated expression of specific marker genes after successful differentiation, with no significant differences regarding different cell source of native tissue. (4) Conclusions: Irrespective of the cell source of native tissue, all MSC-like cells showed multipotent differentiation potential in vitro. The multipotent differentiation capacity did not differ significantly, and chondrogenic differentiation was proven in all pellet cultures. Therefore, cell suitability for cell-based cartilage therapies and tissue engineering is given for various tissue origins that are routinely removed during total knee arthroplasty (TKA). This study might provide essential information for the clinical tool of cell harvesting, leading to more flexibility in cell availability.

  • Open Access

    Dental and Orthopaedic Implant Loosening: Overlap in Gene Expression Regulation

    by Sabine Schluessel, Eliza S. Hartmann, Miriam I. Koehler, Felicitas Beck, Julia I. Redeker, Maximilian M. Saller, Elif Akova, Stefan Krebs, Boris M. Holzapfel, Susanne Mayer-Wagner

    Objectives: Endoprosthetic loosening still plays a major role in orthopaedic and dental surgery and includes various cellular immune processes within peri-implant tissues. Although the dental and orthopaedic processes vary in certain parts, the clinical question arises whether there are common immune regulators of implant loosening. Analyzing the key gene expressions common to both processes reveals the mechanisms of osteoclastogenesis within periprosthetic tissues of orthopaedic and dental origin.Methods: Donor peripheral blood mononuclear cells (PBMCs) and intraoperatively obtained periprosthetic fibroblast-like cells (PPFs) were (co-)cultured with [± macrophage-colony stimulating factor (MCSF) and Receptor Activator of NF-κB ligand (RANKL)] in transwell and monolayer culture systems and examined for osteoclastogenic regulations [MCSF, RANKL, osteoprotegerin (OPG), and tumor necrosis factor alpha (TNFα)] as well as the ability of bone resorption. Sequencing analysis compared dental and orthopaedic (co-)cultures.Results: Monolayer co-cultures of both origins expressed high levels of OPG, resulting in inhibition of osteolysis shown by resorption assay on dentin. The high OPG-expression, low RANKL/OPG ratios and a resulting inhibition of osteolysis were displayed by dental and orthopaedic PPFs in monolayer even in the presence of MCSF and RANKL, acting as osteoprotective and immunoregulatory cells. The osteoprotective function was only observed in monolayer cultures of dental and orthopaedic periprosthetic cells and downregulated in the transwell system. In transwell co-cultures of PBMCs/PPFs profound changes of gene expression, with a significant decrease of OPG (20-fold dental versus 100 fold orthopaedic), were identified. Within transwell cultures, which offer more in vivo like conditions, RANKL/OPG ratios displayed similar high levels to the original periprosthetic tissue. For dental and orthopaedic implant loosening, overlapping findings in principal component and heatmap analysis were identified.Conclusions: Thus, periprosthetic osteoclastogenesis may be a correlating immune process in orthopaedic and dental implant failure leading to comparable reactions with regard to osteoclast formation. The transwell cultures system may provide an in vivo like model for the exploration of orthopaedic and dental implant loosening.